Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BEAM

Beam Therapeutics Inc

Jul 26 • 04:00PM ET

33.14

Dollar change +0.97
Percentage change 3.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK ARKG IWM XBI VTI VB VBK VXF IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.78	Insider Own	6.58%	Shs Outstand	81.63M	Perf Week	27.76%
Market Cap	2.73B	Forward P/E	-	EPS next Y	-4.68	Insider Trans	-17.36%	Shs Float	76.90M	Perf Month	33.41%
Income	-134.74M	PEG	-	EPS next Q	-1.13	Inst Own	81.24%	Short Float	15.68%	Perf Quarter	53.43%
Sales	360.91M	P/S	7.56	EPS this Y	-173.84%	Inst Trans	-0.68%	Short Ratio	9.01	Perf Half Y	32.99%
Book/sh	11.10	P/B	2.99	EPS next Y	0.55%	ROA	-10.01%	Short Interest	12.06M	Perf Year	3.21%
Cash/sh	13.30	P/C	2.49	EPS next 5Y	-3.70%	ROE	-16.09%	52W Range	16.95 - 49.50	Perf YTD	21.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-12.60%	52W High	-33.05%	Beta	1.81
Dividend TTM	-	Quick Ratio	5.99	Sales past 5Y	43297.50%	Gross Margin	92.92%	52W Low	95.52%	ATR (14)	1.80
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.99	EPS Y/Y TTM	60.93%	Oper. Margin	-50.34%	RSI (14)	73.83	Volatility	8.57% 6.01%
Employees	436	Debt/Eq	0.18	Sales Y/Y TTM	370.57%	Profit Margin	-37.33%	Recom	1.88	Target Price	50.07
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	9.51%	Payout	-	Rel Volume	0.81	Prev Close	32.17
Sales Surprise	-56.63%	EPS Surprise	14.50%	Sales Q/Q	-69.39%	Earnings	May 07 BMO	Avg Volume	1.34M	Price	33.14
SMA20	28.80%	SMA50	33.35%	SMA200	23.41%	Trades		Volume	1,090,244	Change	3.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$85
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight	$47 → $90
Feb-16-21	Initiated	Wells Fargo	Overweight	$145

Show Previous Ratings

Today 07:43AM	Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? (Zacks)
Jul-24-24 06:28PM	Beam Therapeutics Stock Earns RS Rating Jump To 85 (Investor's Business Daily) +7.92%
08:53AM	CRISPR Therapeutics Nears 52-Week Low. Time to Buy? (TipRanks)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-16-24 10:12AM	Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines (Zacks) +6.52%
06:30AM	Loading…
Jul-15-24 06:30AM	Beam Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jul-11-24 12:56PM	Here's Why You Should Invest in Beam Therapeutics (BEAM) Now (Zacks) +8.01%
Jul-09-24 12:00PM	Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
06:25AM	3 Stocks With the Potential to 10X Your Money (InvestorPlace)
Jul-04-24 02:13PM	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals (InvestorPlace)
Jul-03-24 09:12AM	3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 (InvestorPlace)
Jun-27-24 10:02PM	You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. (InvestorPlace)
10:26AM	Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study (Zacks)
Jun-26-24 06:30AM	Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
03:00AM	Loading…
Jun-14-24 03:00AM	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report? (Zacks)
May-30-24 06:30AM	Beam Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 04:00PM	Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress (GlobeNewswire)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey) +12.98%
May-09-24 06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 10:52AM	Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss (Zacks)
06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference (GlobeNewswire)
May-07-24 09:02PM	Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview (GuruFocus.com)
01:54PM	BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:17AM	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
06:30AM	Loading…
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47% -8.66%
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98% -9.14%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 01:04PM	Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates (Zacks)
Nov-08-23 06:30AM	Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire) -8.36%
06:30AM	Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-01-23 05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +10.62%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)
10:00AM	After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? (Motley Fool)
06:00AM	Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:18AM	5 Reasons Beam Therapeutics Remains a Risky Stock (Motley Fool)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-25-23 06:30AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT (GlobeNewswire)
05:50AM	Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? (Motley Fool)
01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-21-23 08:45AM	Beam Therapeutics Stock: Bear vs. Bull (Motley Fool)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
09:37AM	SolarEdge downgraded, Crocs upgraded: Wall Street's top analyst calls (The Fly)
Oct-19-23 09:03AM	UPDATE 2-Beam Therapeutics to cut 20% of workforce as part of restructuring plan (Reuters) -11.73%
08:54AM	Beam Therapeutics to cut 20% of workforce (Reuters)
08:45AM	Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline (GlobeNewswire)
Oct-18-23 09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool) -6.60%
Oct-05-23 08:45AM	2 Cathie Wood Stocks I'm Bullish On (Motley Fool)
Oct-03-23 06:27AM	Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? (Motley Fool)
Sep-29-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Sep-27-23 08:30AM	2 Magnificent Growth Stocks to Buy On the Dip (Motley Fool)
Sep-22-23 05:50AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too (Motley Fool)
Sep-08-23 08:20AM	This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It. (Motley Fool)
07:23AM	Cathie Wood's Buying These 3 Stocks Hand Over Fist (Motley Fool)
Sep-07-23 10:00AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation (GlobeNewswire)
Sep-05-23 06:30AM	Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL (GlobeNewswire)
Aug-31-23 07:37AM	10 Stocks That Could 10X Over the Next 10 Years (Insider Monkey)
06:30AM	Beam Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-26-23 07:50AM	3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street (Motley Fool)
Aug-19-23 05:52AM	Got $200? 3 Growth Stocks to Buy That Could Double Your Money (Motley Fool)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM
Evans John M.	CEO	Jun 27 '24	Sale	24.50	60,000	1,470,156	998,343	Jun 28 04:15 PM
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 03 '24	Sale	26.42	1,907	50,383	80,495	Jan 05 04:30 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Option Exercise	7.22	10,000	72,200	92,402	Nov 22 04:05 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Sale	30.50	10,000	305,000	82,402	Nov 22 04:05 PM
Simon Amy	Chief Medical Officer	Oct 30 '23	Sale	18.70	3,448	64,478	65,469	Nov 01 04:30 PM
Ciaramella Giuseppe	President and CSO	Oct 20 '23	Option Exercise	0.67	90,900	60,903	139,150	Oct 24 04:05 PM
Bellon Christine	Chief Legal Officer	Oct 02 '23	Sale	22.85	388	8,866	82,402	Oct 04 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience